Tristel plc

("Tristel" or the "Company")

Exercise of Share Options and Total Voting Rights

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that it has issued and allotted a total of 25,500 new ordinary shares of 1 penny each in the capital of the Company ("Ordinary Shares") following the exercise of options by employees of the Group.

Application has been made to the London Stock Exchange for the 25,500 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 1 November 2024.

Total Voting Rights

After Admission, the total number of Ordinary Shares in issue will be 47,675,593 and the total number of voting rights will therefore be 47,675,593. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information please contact:     

About Tristel plc

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO₂) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the Tristel brand, and under the Cache brand provides products for sporicidal surface disinfection, in a format which is a sustainable alternative to commonly used pre-wetted plastic wipes.

Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 250 people across 14 subsidiaries selling into 40 countries.

The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).

For more information about Tristel's product range please visit: https://tristel.com